Overview

• MET-097i achieved up to a 14.1% mean placebo-subtracted weight loss after 28 weekly doses in the VESPER-1 Phase 2b trial, with an exploratory 36-week extension showing continued decline without a plateau.
• An interim VESPER-3 analysis of a three-step titration to 1.2 mg reported nausea and vomiting rates 13 and 11 percentage points above placebo with little diarrhea, indicating a potentially favorable tolerability profile.
• Only 2 of 239 participants (2.9%) in VESPER-1 discontinued due to adverse events, though detailed safety data have not yet been released.
• Metsera is developing a once-monthly dosing regimen supported by the drug’s long half-life, with VESPER-3 weight-loss topline expected by late 2025 or early 2026 and a global Phase 3 launch planned for late 2025.
• Pfizer agreed to acquire Metsera in a multibillion-dollar deal reported at $4.9 billion or up to $7.3 billion including contingent payments, with closing expected by year-end.